What GlyTherix Ltd. does

GlyTherix Ltd. is an Australian private biotechnology company focused on targeted radiotherapy, headquartered in Sydney and founded in 2017. The company operates in the radiopharmaceutical space, which typically involves the development of biological targeting agents (such as antibodies or small molecules) conjugated to therapeutic radioisotopes designed to deliver localized radiation to cancer cells while sparing healthy tissue. The firm's strategic positioning is consistent with the broader global shift toward precision oncology and theranostics, though the specific molecular targets, radioisotopes, and indication areas are not disclosed in the available source data.

The company is small-scale, with 1–10 employees per the firmographic data, and operates as a privately held for-profit entity. Brad Walsh is identified as Chief Executive Officer. There is no disclosed product portfolio, pricing model, manufacturing capability, clinical pipeline, regulatory filing status, or partnership structure in the provided inputs. The company website (glytherix.com) was not accessible for content extraction at the time of data collection, which itself limits the verification surface for the company's claims.

GlyTherix's business model cannot be characterized from the available data. There are no disclosed revenue streams, no funding round history, no named customers or licensing partners, no app or digital product surface, and no certifications or compliance disclosures. The absence of these standard data points means that commercialization pathway, capital structure, and go-to-market mechanics are unknown — a material gap for any investment-grade assessment of an early-stage radiopharmaceutical developer.

Name

GlyTherix Ltd.

Website

https://glytherix.com

Company type

Private

Founded year

2017

Headcount range

1–10 employees

Short description

GlyTherix Ltd. is a privately held Australian biotechnology company founded in 2017 in Sydney, developing targeted radiotherapy treatments. The firm operates at a small scale (1–10 employees) under CEO Brad Walsh, with no disclosed product pipeline or commercial stage in the available data.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

Keywords

• Targeted radiotherapy
• Radiopharmaceutical oncology
• Cancer radioimmunotherapy
• Antibody radiotherapy
• Oncology therapeutics

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

GlyTherix Ltd. is an Australian targeted radiotherapy company developing targeted radiotherapy treatments. The company focuses on radiotherapy-based approaches for cancer therapy, operating in the radiopharmaceutical/biotech space from its base in Sydney, Australia.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Broad incumbents

• Novartis: Global pharma with the leading commercial radioligand therapy franchise (Lutathera, Pluvicto). Broad incumbent that defines the commercial benchmark for targeted radiotherapeutics and sets competitive pressure on niche entrants.
• Lantheus Holdings: U.S. radiopharmaceutical-focused company with diagnostic and emerging therapeutic assets (e.g., PNT2002/PNT2003 programmes). Comparable as an established specialty radiopharma operator with both imaging and therapeutic franchises.
• Bayer: Diversified pharma with a commercial radiotherapeutic (Xofigo) and active investment in next-generation targeted radionuclide therapies through its Radioligand Therapy platform. Comparable as a broad incumbent in therapeutic radiopharma.

Regional players

• Telix Pharmaceuticals: ASX-listed Australian radiopharmaceutical company developing diagnostic and therapeutic radiopharmaceuticals across oncology. Closely comparable as an Australian-headquartered peer in the same therapeutic and diagnostic radiopharma category.
• Clarity Pharmaceuticals: ASX-listed Sydney-based radiopharmaceutical company developing targeted radiopharmaceuticals for oncology. Direct regional peer sharing Australian roots, similar size profile historically, and an overlapping theranostic and targeted radiotherapy thesis.

Emerging players

• Moleculin Biotech: U.S. clinical-stage company developing radiolabelled therapeutics and oncology drug candidates. Comparable as a smaller, earlier-stage radiotherapeutics developer with a similar need to attract capital or strategic partners.

Direct peers

• RayzeBio: Clinical-stage radiopharmaceutical company developing actinium-225-based targeted radiotherapeutics for solid tumours (acquired by Bristol Myers Squibb). Direct peer in the targeted radiotherapy category, illustrative of the M&A exit path for such assets.
• Fusion Pharmaceuticals: Clinical-stage developer of targeted alpha therapies (acquired by AstraZeneca). Direct peer in the targeted radiotherapeutics category, with a comparable development-stage platform thesis.
• Point Biopharma: Clinical-stage radiopharmaceutical company developing targeted radioligand therapies for oncology (acquired by Eli Lilly). Direct peer as a focused targeted radiotherapy developer with a comparable asset profile.
• ITM Isotope Technologies Munich: German radiopharmaceutical company developing targeted radionuclide therapies and producing medical radioisotopes. Direct peer in the targeted radiotherapeutics category, with both development pipeline and isotope production capabilities.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/glytherix

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GlyTherix Ltd.